R E Pounder
Overview
Explore the profile of R E Pounder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
223
Citations
3267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Lee C, Wyeth J, Sercombe J, Pasi K, Lee C, Pounder R
Haemophilia
. 2016 May;
3(4):288-91.
PMID: 27214866
The aim of this study was to identify and eradicate H. pylori infection in patients with haemophilia. Patients were screened for IgG antibodies against H. pylori; active infection was determined...
3.
Thompson N, Wakefield A, Pounder R
Saudi J Gastroenterol
. 2009 Oct;
1(3):129-37.
PMID: 19864844
The chance of normal survival for patients with inflammatory bowel disease is generally good. There may be a small excess mortality for those with Crohn's disease; however recent studies do...
4.
Puleston J, Cooper M, Murch S, Bid K, Makh S, Ashwood P, et al.
Aliment Pharmacol Ther
. 2005 Feb;
21(2):109-20.
PMID: 15679760
Background: Inflammatory bowel disease (IBD) is characterised by intense mucosal recruitment of activated leukocytes. Chemokines determine inflammatory leukocyte recruitment and retention. Aim: To compare expression of the entire chemokine family...
5.
Dunnill M, Pounder R
Clin Med (Lond)
. 2004 Mar;
4(1):45-9.
PMID: 14998266
This article reviews the current literature relating to medical outpatient services. It has been produced as part of the RCP/NHS Confederation working party on outpatients departments. The article deals with...
6.
Ehlin A, Montgomery S, Ekbom A, Pounder R, Wakefield A
Gut
. 2003 Jul;
52(8):1117-21.
PMID: 12865268
Background: Few studies have investigated the prevalence of multiple gastrointestinal diseases in the general British population. Aim: To examine the prevalence of Crohn's disease (CD), ulcerative colitis (UC), irritable bowel...
7.
Williams M, Usselmann B, Chilton A, Sercombe J, Nwokolo C, Pounder R
Aliment Pharmacol Ther
. 2003 Mar;
17(6):775-83.
PMID: 12641499
Background: The eradication of Helicobacter pylori decreases the antisecretory activity of omeprazole and lansoprazole. Rabeprazole is a potent proton pump inhibitor that may not be affected as greatly by H....
8.
Montgomery S, Lambe M, Wakefield A, Pounder R, Ekbom A
Scand J Gastroenterol
. 2002 Dec;
37(11):1301-8.
PMID: 12465729
Background: Environmental exposures in early life have been implicated in the aetiology of inflammatory bowel disease (IBD). Siblings are used as proxy markers to characterize patterns of exposure relevant to...
9.
Brett B, Smith S, Bouvier C, Michaeli D, Hochhauser D, Davidson B, et al.
J Clin Oncol
. 2002 Oct;
20(20):4225-31.
PMID: 12377966
Purpose: The prognosis for advanced pancreatic cancer remains poor. Gastrin acts as a growth factor for pancreatic cancer. We describe the first study of the antigastrin immunogen G17DT in pancreatic...
10.
Gordon F, Hamilton M, Donoghue S, Greenlees C, Palmer T, Dhillon A, et al.
Aliment Pharmacol Ther
. 2002 Apr;
16(4):699-705.
PMID: 11929387
Background: Alpha-4 integrins facilitate leucocyte migration across vascular endothelium. Aim: To assess the safety and efficacy of natalizumab (Antegren), a humanized antibody to alpha-4 integrin, in patients with active ulcerative...